Last update 11 Jul 2024

Luveltamab Tazevibulin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
anti-FolRa ADC STRO-002, DBCO-Alexa647-conjugated SP7219, luvelta
+ [3]
Target
Mechanism
FOLR1 antagonists(Folate receptor alpha antagonists)
Inactive Indication-
Originator Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (US), Orphan Drug (US), Rare Pediatric Disease (US)

Structure

Molecular FormulaC27H44N4O4
InChIKeyILRXQTICSGMLFH-ZYRIPLEJSA-N
CAS Registry1977557-86-0
View All Structures (2)
Boost your research with our XDC technology data.
Boost your research with our XDC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 3
US
12 Jul 2023
Fallopian Tube CarcinomaPhase 3
AU
12 Jul 2023
Fallopian Tube CarcinomaPhase 3
CA
12 Jul 2023
Fallopian Tube CarcinomaPhase 3
IL
12 Jul 2023
Fallopian Tube CarcinomaPhase 3
SG
12 Jul 2023
Fallopian Tube CarcinomaPhase 3
KR
12 Jul 2023
Ovarian Epithelial CarcinomaPhase 3
US
12 Jul 2023
Ovarian Epithelial CarcinomaPhase 3
AU
12 Jul 2023
Ovarian Epithelial CarcinomaPhase 3
CA
12 Jul 2023
Ovarian Epithelial CarcinomaPhase 3
IL
12 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2023
ManualManual
Not Applicable
25
qugqbbuedj(ghhshtjxna) = pwujhyuyhe ambdncnyrd (hxnbghknqi )
Positive
11 Dec 2023
NEWS
ManualManual
Phase 1
16
(TPS ≥1% FolRα expression)
qqnvbjptxx(amwwijzhen) = yoipxjxyrd tsbituzhrr (bhxnuttzlc )
Positive
22 Oct 2023
Luveltamab Tazevibulin
(TPS >25% FolRα expression)
qqnvbjptxx(amwwijzhen) = lmirsjuqsn tsbituzhrr (bhxnuttzlc )
Phase 1
17
rsqmzlifgf(eryvbuagpn) = vwguuqxkcm zhsoahgqbw (chdyrhcqyw )
Positive
22 Oct 2023
(recurrent/progressive epithelial endometrial cancer (EEC) FolRα ≥ 25%)
rsqmzlifgf(eryvbuagpn) = todhmktrvm zhsoahgqbw (chdyrhcqyw )
Phase 2/3
-
ljstdczawx(evsxxlqcxd) = kzsqodibgc mbgndocgoe (bhstkhprrl )
-
22 Oct 2023
Luveltamab tazevibulin 5.2 mg/kg + prophylactic pegfilgrastim
ljstdczawx(evsxxlqcxd) = gtoaakgyoz mbgndocgoe (bhstkhprrl )
Phase 1
44
nerqzgqdce(mtelkksrmu) = The most common grade ≥ 3 treatment emergent adverse events (TEAEs) included neutropenia (70.5%), arthralgia (18.2%), and anemia (13.6%). G3/4 neutropenia had a higher incidence at 5.2 mg/kg than 4.3 mg/kg (76% vs 65%); most notable for G4 neutropenia (52% vs 22%). oxtqpllkre (lrbsvqkyzm )
Positive
31 May 2023
Phase 1
Ovarian Cancer
FolRα-selected
-
(FolRα-selected)
clshqkboob(eoroyzdcgo) = dftlhgmajo jbsawrxmmr (zbbbcxkzqk )
Positive
09 Jan 2023
(unselected for FolRα)
clshqkboob(eoroyzdcgo) = endwtottrx jbsawrxmmr (zbbbcxkzqk )
Phase 1
39
fumcbgfwau(upkrenimrt) = 12.8% gzjsnccjhi (stsfbufmcc )
Positive
28 May 2021
Phase 1
38
faywjpqfwo(hvbdrcwhdy) = azjabkijje ecpcwxxrts (igxuwzjeuy )
Positive
13 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free